COMP <GO>
SRRK vs ABBV // PIOTROSKI F-SCORE QUALITY
Scholar Rock Holding Corporation (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: SRRK 4
— ABBV 10
▲ PIOTROSKI F-SCORE QUALITY LEADER: ABBV
LAST: $43.90 (-0.63%) • MKT CAP: $5.38B
piotroski-score
5/9
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SRRK VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SRRK | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 44.00% | 70.20% | -26.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 29.00% | -64.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.59% | 3.47% | -9.06 | ABBV | /fcf-yield <GO> |
| Operating Margin | 16.50% | 24.60% | -8.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 6.90% | +5.50 | SRRK | /net-margins <GO> |
| Revenue Growth (YoY) | 7.70% | 8.60% | -0.90 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 13.67 | 5.33 | +8.34 | SRRK | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 7.40% | -0.40 | SRRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.2 | 72.8 | -23.54 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 1.15 | -0.13 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 113.1x | -81.10 | SRRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.38B | $513.86B | -$508.48B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SRRK REV | ABBV REV | SRRK GROSS % | ABBV GROSS % | SRRK FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $61.16B | — | 70.2% | -$300.6M | $17.82B |
| FY 2024 | $0 | $56.33B | — | 70.0% | -$201.0M | $17.83B |
| FY 2023 | $0 | $54.32B | — | 44.0% | -$145.2M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SRRK // BETA 1.02
ABBV // BETA 1.15